Fortress Biotech Future Growth
Future criteria checks 2/6
Fortress Biotech's earnings are forecast to decline at 7.1% per annum while its annual revenue is expected to grow at 25.4% per year. EPS is expected to grow by 22.1% per annum.
Key information
-7.1%
Earnings growth rate
22.1%
EPS growth rate
Biotechs earnings growth | 24.8% |
Revenue growth rate | 25.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 16 May 2024 |
Recent future growth updates
Recent updates
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Dec 29There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Aug 18Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients
Aug 11David Jin is the new finance chief of Fortress Biotech
Jul 22Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?
Jan 11Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?
Sep 28Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?
Jun 04Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?
Mar 04When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?
Feb 06Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares
Jan 11Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder
Dec 15Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?
Dec 15Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?
Nov 19Fortress Biotech EPS misses by $0.02, misses on revenue
Nov 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 168 | -75 | N/A | N/A | 2 |
12/31/2025 | 126 | -76 | N/A | N/A | 3 |
12/31/2024 | 74 | -89 | N/A | N/A | 3 |
3/31/2024 | 85 | -63 | -113 | -110 | N/A |
12/31/2023 | 85 | -69 | -136 | -128 | N/A |
9/30/2023 | 62 | -78 | -150 | -141 | N/A |
6/30/2023 | 63 | -96 | -176 | -168 | N/A |
3/31/2023 | 64 | -92 | -182 | -176 | N/A |
12/31/2022 | 76 | -95 | -202 | -179 | N/A |
9/30/2022 | 78 | -97 | -196 | -170 | N/A |
6/30/2022 | 82 | -93 | -181 | -149 | N/A |
3/31/2022 | 81 | -74 | -179 | -142 | N/A |
12/31/2021 | 69 | -65 | -133 | -117 | N/A |
9/30/2021 | 64 | -38 | -113 | -98 | N/A |
6/30/2021 | 53 | -33 | -110 | -101 | N/A |
3/31/2021 | 44 | -43 | -89 | -83 | N/A |
12/31/2020 | 46 | -47 | -91 | -84 | N/A |
9/30/2020 | 43 | -57 | -99 | -88 | N/A |
6/30/2020 | 43 | -54 | -92 | -81 | N/A |
3/31/2020 | 43 | -54 | -102 | -92 | N/A |
12/31/2019 | 37 | -40 | -104 | -95 | N/A |
9/30/2019 | 34 | -45 | -98 | -92 | N/A |
6/30/2019 | 30 | -51 | -106 | -101 | N/A |
3/31/2019 | 27 | -53 | -105 | -96 | N/A |
12/31/2018 | 27 | -73 | -108 | -99 | N/A |
9/30/2018 | -107 | -61 | -107 | -98 | N/A |
6/30/2018 | -65 | -69 | -105 | -98 | N/A |
3/31/2018 | -22 | -72 | -102 | -98 | N/A |
12/31/2017 | 17 | -65 | N/A | -81 | N/A |
9/30/2017 | 155 | -74 | N/A | -78 | N/A |
6/30/2017 | 109 | -60 | N/A | -62 | N/A |
3/31/2017 | 61 | -55 | N/A | -46 | N/A |
12/31/2016 | 16 | -55 | N/A | -46 | N/A |
9/30/2016 | 4 | -50 | N/A | -35 | N/A |
6/30/2016 | 3 | -55 | N/A | -31 | N/A |
3/31/2016 | 1 | -49 | N/A | -30 | N/A |
12/31/2015 | 1 | -48 | N/A | -20 | N/A |
9/30/2015 | 1 | -40 | N/A | -17 | N/A |
6/30/2015 | 1 | -27 | N/A | -14 | N/A |
3/31/2015 | 1 | -25 | N/A | -12 | N/A |
12/31/2014 | N/A | -20 | N/A | -16 | N/A |
9/30/2014 | N/A | -26 | N/A | -20 | N/A |
6/30/2014 | N/A | -30 | N/A | -24 | N/A |
3/31/2014 | N/A | -36 | N/A | -28 | N/A |
12/31/2013 | N/A | -37 | N/A | -30 | N/A |
9/30/2013 | N/A | -36 | N/A | -30 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FBIO's revenue (25.4% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: FBIO's revenue (25.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FBIO's Return on Equity is forecast to be high in 3 years time